FDA Grants Fast Track to PureTech’s MDS Antibody

FDA has granted Fast Track designation to LYT-200, an antibody being developed by Gallop Oncology — a company founded and wholly owned by PureTech Health — for relapsed or refractory high-risk myelodysplastic syndromes. The company announced the designation on 20 September 2026 together with the outcome of a separate, and separately consequential, meeting: a completed End-of-Phase 1 discussion with FDA that it says clears a path into a placebo-controlled Phase 2 trial.

What Fast Track actually buys a sponsor

Fast Track designation is not an approval, and it does not shorten a clinical trial. What it does is procedural: more frequent meetings and written communication with the review division, and eligibility for rolling review, in which a sponsor can submit completed portions of a marketing application before the rest is ready, rather than waiting to file everything at once. For a company the size of Gallop Oncology — a subsidiary operating inside PureTech's “hub-and-spoke” model of founding and funding separate biotechs around individual drug candidates — that kind of standing access to FDA's review division is itself a resource, independent of anything the designation says about the drug's eventual approval odds.

The target: galectin-9, not a mutation

Myelodysplastic syndromes are a group of bone-marrow disorders in which blood cell production is disrupted; the high-risk subset carries an elevated risk of progression to acute myeloid leukemia, and patients who relapse after or become refractory to hypomethylating agents — the current mainstay therapy — have few options. LYT-200 targets galectin-9, a protein Gallop Oncology describes as functioning both as an oncogenic driver and as an immunosuppressor, with expression the company says is elevated in HR-MDS. The pitch is deliberately mutation-agnostic: rather than targeting a specific genetic alteration present in a subset of patients, as many precision oncology drugs do, LYT-200 is designed against a biological mechanism the company argues is broadly present across the HR-MDS population — including, it says, the majority of patients without an actionable mutation to target.

The evidence behind the designation

The company's own public backing for this comes from an earlier, separate disclosure: Phase 1b topline data reported on 22 April 2026 in a small efficacy-evaluable cohort of 11 R/R HR-MDS patients treated at the recommended Phase 2 dose (12 mg/kg LYT-200 plus a hypomethylating agent), a group with a median of three prior lines of therapy and where all patients had already failed a hypomethylating agent. In that cohort, the company reported a 27.3% complete response rate, a combined complete-plus-partial response rate of 36.3%, and an overall response rate of 45.5%. Those figures are five months old, from a very small sample, and were not reissued or updated in this week's announcement — they are background for the Fast Track decision, not new data. FDA does not publish the substance of Fast Track reviews or disclose the IND application involved, so the designation itself carries no additional efficacy figures beyond what the company has already made public.

The Phase 2 design

• STRIDE-MDS is designed as a randomized, double-blind, placebo-controlled trial in R/R HR-MDS, with an approximate 125-patient enrollment target.
• A 2:2:1 randomization splits patients across three arms: LYT-200 at 12 mg/kg plus a hypomethylating agent, LYT-200 at 7.5 mg/kg plus a hypomethylating agent, and a hypomethylating agent plus placebo.
• The two-dose comparison is built around FDA's Project Optimus initiative, which pushes oncology sponsors to justify a dose against comparative data rather than defaulting to the maximum tolerated dose from earlier trials.
• Eric Elenko, PhD, Gallop Oncology's acting CEO and a PureTech co-founder, said in the company's statement: “Our productive End-of-Phase 1 meeting with the U.S. FDA provides a clear path to advance LYT-200 into Phase 2 development.”

PureTech's model

PureTech Health plc trades solely on the London Stock Exchange (LSE: PRTC) after voluntarily delisting its Nasdaq-traded American Depositary Shares in May 2026; it operates from a headquarters in Boston's Seaport District. Gallop Oncology is one of the “Founded Entities” in PureTech's hub-and-spoke structure — a company PureTech created and wholly owns to advance a specific program, LYT-200, rather than a fully independent biotech. That structure means a designation like this one is a milestone for the parent's pipeline economics as much as for the drug itself: it is the kind of regulatory progress PureTech can point to in valuing a Founded Entity ahead of any eventual spinout, partnership, or sale.

Frequently asked questions

What did FDA grant PureTech's LYT-200?

Fast Track designation, for LYT-200 in combination with a hypomethylating agent (azacitidine or decitabine) in relapsed/refractory high-risk myelodysplastic syndromes (R/R HR-MDS). Gallop Oncology, the PureTech Health company developing the drug, announced the designation on 20 September 2026 alongside a separately reported successful End-of-Phase 1 meeting with FDA.

What is LYT-200?

An antibody targeting galectin-9, which Gallop Oncology describes as both an oncogenic driver and an immunosuppressor in HR-MDS. The rationale is that blocking galectin-9 works on the disease's underlying biology rather than a specific mutation, potentially extending the drug's reach to patients without an actionable mutation to target.

What comes next?

STRIDE-MDS: a randomized, double-blind, placebo-controlled Phase 2 trial enrolling roughly 125 patients with R/R HR-MDS, comparing two LYT-200 doses (12 mg/kg and 7.5 mg/kg, each plus a hypomethylating agent) against a hypomethylating agent plus placebo, in a design built around FDA's Project Optimus dose-selection framework.

Is this LYT-200's first Fast Track designation?

No — its third. FDA previously granted Fast Track status to LYT-200 in acute myeloid leukemia in January 2025 and separately in head and neck cancer. This is the first Fast Track grant specific to R/R HR-MDS.